NCT06963203 Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis
| NCT ID | NCT06963203 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Andrea Goldmann |
| Condition | Graves Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 486 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2027-06 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this observational study is to learn about the potential differences in morbidity of thyroidectomy (removal of the thyroid gland) depending on the preoperative hormonal status. The main question it aims to answer is: Do patients undergoing thyroidectomy for thyreotoxicosis (thyroid hyperfunction) due to Graves' disease or Amiodarone induced thyreotoxicosis have comparable complication rates depending on their thyroid metabolic status prior or during the procedure. The data from participants undergoing a thyroidectomy at one of the study sites will be prospectively registered in the EUROCRINE registry, including an add-on module for additional study specific routine data. The operation itself, the preoperative or postoperative treatments are not altered in any way.
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥ 18 years of age) undergoing surgical treatment for Graves' disease or Amiodarone-induced thyrotoxicosis (AIT) with biochemically confirmed hyperthyroidism or on specific medication for the treatment of Graves' disease or AIT. * Patients providing signed informed consent. Exclusion Criteria: * Children and minors (\<18 years). * Pregnant women. * Patients unable or unwilling to provide informed consent due to language barriers or intellectual limitations. * Patients undergoing concurrent parathyroidectomy for primary or secondary hyperparathyroidism, lymph node clearance, or redo surgery. * Surgical procedures performed for other reasons than Graves' disease or AIT